source
- Immunovant halts lupus program after Phase 2b trial fails to meet efficacy endpointsImmunovant announced that its anti‑FcRn drug imeroprubart (IMVT‑1402) did not achieve the primary endpoint in a Phase 2b study in patients with cutaneous lupus erythematosus. The double‑blind tria…
- ReCode Therapeutics appoints Heather Clark as CEO to lead cystic fibrosis and primary ciliary dyskinesia programsReCode Therapeutics announced that Heather Clark will take over as chief executive officer, succeeding founder Shehnaaz Suliman. The transition was presented as a move to keep momentum after the co…